All Photos(1)



PKCε Translocation Inhibitor II, PKCe141 - Calbiochem

A cell-permeable inhibitor of PKCε-RACK2 interaction (IC₅₀ = 5.9 µM).

PKCε Translocation Inhibitor II, PKCe141 - Calbiochem, N-(3-Acetylphenyl)-9-amino-2,3-dihydro-[1,4]dioxino[2,3-g]thieno[2,3-b]quinoline-8-carboxamide, PKCε-RACK2 Interaction Inhibitor II, Protein Kinase Cε Translocation Inhibitor II
Empirical Formula (Hill Notation):
Molecular Weight:


≥95% (HPLC)

Quality Level





storage condition

OK to freeze
protect from light




DMSO: 10 mg/mL

storage temp.


General description

A cell-permeable non-peptidic thienoquinoline modeled after pharmacophore feature derived from the non-permeant EAVSLKPT (Cat. no. 539522) and found to selectively inhibit PKCε-RACK2, but not PKCβII-RACK1, interaction (IC50 = 5.9 µM; [RACK2-MBP] = 500 ng/50 µL or 62.5 nM) and suppress PKCε, but not PKCδ membrane translocation induced by PMA/TPA (Cat. nos. 500582 & 524400) in serum-starved PC-3 cultures (20 or 50 µM PKCe141 added 30 min prior to 50 or 100 nM TPA stimulation for 5 min). Likewise, PKCe141 is demonstrated to inhibit Elk-1 activation domain (aa 307-427) phosphorylation-dependent HeLa luciferase reporter (HLR) transcription (IC50 = 11.2 µM) as well as MARCKS S152/S156 phosphorylation in serum-starved HeLa cells (50 µM) upon TPA stimulation without cytotoxicity (up to 50 µM for 72 h by SRB assay). PKCe141 does not inhibit cellular PKCε phosphorylation and exhibits little potency against PKC kinase activity (% inhibition at 50 µM/150 ng PKC = 23/η, 18/βI, 17/α, 12/ε, 11/γ, 9/ι, 6/δ & θ, 1/βII, 0/ζ; [ATP] = 40 µM; substrate [PKCα 19-31] = 50 µM), while more significant inhibition is seen against 5 other kinases among a panel of 109, the observed potency (% inhibition at 50 µM = 73/RSK2, 58/BTK, 54/PIM3, 51/NUAK1, 45/ERK1) is less than that toward PKCε-RACK2 interaction. Also reported to suppress active PKCε-dependent HeLa migration (25 µM for 24 h) and inhibit VEGF-induced angiogenesis in chicken eggs (10 ng VEGF & 10 ng PKCe141).
A cell-permeable, non-toxic thienoquinoline compound that dose-dependently inhibits PKCε-RACK2 interaction (IC50 = 5.9 µM). Shown to occupy PKCε to RACK2 binding site in a reversible manner and block cellular phosphorylation of MARCKS and Elk-1 (IC50 = 11.2 µM in HeLa cells). Prevents TPA-induced PKCε translocation to the plasma membrane, and reduces PKCε-induced cell migration, invasion and suppresses angiogenesis. Displays desireable selectivity in a 109-kinase panel, and at higher concentrations affects PKCα, βI and ζ (~80% at 50 µM) and ERK1, RSK2, NUAK1, PIM3 & BTK (>50% at 25 µM) activities.

Please note that the molecular weight for this compound is batch-specific due to variable water content.


20 mg in Glass bottle
Packaged under inert gas

Biochem/physiol Actions

Cell permeable: yes
Primary Target
Reversible: yes


Toxicity: Standard Handling (A)


Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Rechfeld, F., et al. 2014. J. Med. Chem.57, 3235.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Quality

Enter Lot Number to search for Certificate of Quality (COQ).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service